Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-aflibercept in macular diseases
NCT02556723Completed
- Sponsor
- The Retina Clinic London
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Countries
- 1
01
Overview
Open-label trial of aflibercept in diabetic macular edema (DME), neovascular age-related macular degeneration (NVAMD), branch retinal vein occlusion (BRVO) and 1 more, sponsored by The Retina Clinic London. Primary endpoint: Multifocal electroretinogram responses at 48 weeks. Started Sep 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)branch retinal vein occlusion (BRVO)central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT02556723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556723.